Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03234478 · ClinicalTrials.gov registry record
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 150
- Enrollment target
NCT03234478 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 150 participants.
The verdict
NCT03234478 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
Every year, approximately 9,000 Parkinson disease (PD) patients undergo deep brain stimulator (DBS) placement into the subthalamic nucleus (STN-DBS). Studies suggest that PD patients with mutations in the glucocerebrosidase (GBA) gene are at high risk for cognitive impairment and approximately 10-17% of subjects undergoing DBS carry GBA mutations. There may be an interaction between STN-DBS, which also impairs cognitive function, and GBA, resulting in worsened cognitive function. This project will 1) determine the relationship between GBA mutation status and post-operative STN-DBS cognitive function, 2) broaden genotype-phenotype relationships of GBA mutation carriers and 3) provide scientific knowledge regarding the longitudinal cognitive effects of DBS in GBA mutation carriers through repeated neuropsychological testing.
Interventions
- OTHER cognitive assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2024-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234478
The ClinicalTrials.gov registry entry for NCT03234478 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cognitive assessments is the first listed.
NCT03234478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03234478 about?
NCT03234478 is a clinical study titled "Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers". Every year, approximately 9,000 Parkinson disease (PD) patients undergo deep brain stimulator (DBS) placement into the subthalamic nucleus (STN-DBS). Studies suggest that PD patients with mutations in the glucocerebrosidase (GBA) gene are at high risk for cognitive impairment and approximately 10-17...
What is the current status of trial NCT03234478?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2017-07-01. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03234478?
The interventions under investigation include: cognitive assessments (OTHER).
Who is sponsoring clinical trial NCT03234478?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.